Main Article Content
Hyperuricemia - a condition characterized by elevated relative to normal ranges, levels of uric acid in the blood. Among the diseases caused by hyperuricemia, most noteworthy are gout, urate nephropathy, and urolithiasis. The topic of this article is devoted to the comparative characteristics of drugs used to correct hyperuricemia. The main part of the article is an analysis of pharmacodynamics, efficacy, safety and expediency of using orotic acid agents.
This work is licensed under a Creative Commons Attribution 4.0 International License.
Our edition uses the copyright terms of Creative Commons for open access journals.
Authors, who are published in this journal, agree with the following terms:
- The authors retain rights for authorship of their article and grant to the edition the right of first publication of the article on a Creative Commons Attribution 4.0 International License, which allows others to freely distribute the published article, with the obligatory reference to the authors of original works and original publication in this journal.
- Directing the article for the publication to the editorial board (publisher), the author agrees with transmitting of rights for the protection and using the article, including parts of the article, which are protected by the copyrights, such as the author’s photo, pictures, charts, tables, etc., including the reproduction in the media and the Internet; for distributing; for the translation of the manuscript in all languages; for export and import of the publications copies of the writers’ article to spread, bringing to the general information.
- The rights mentioned above authors transfer to the edition (publisher) for the unlimited period of validity and on the territory of all countries of the world.
- The authors guarantee that they have exclusive rights for using of the article, which they have sent to the edition (publisher). The edition (the publisher) is not responsible for the violation of given guarantees by the authors to the third parties.
- The authors have the right to conclude separate supplement agreements that relate to non-exclusive distribution of their article in the form in which it had been published in the journal (for example, to upload the work to the online storage of the journal or publish it as part of a monograph), provided that the reference to the first publication of the work in this journal is included.
- The policy of the journal permits and encourages the publication of the article in the Internet (in institutional repository or on a personal website) by the authors, because it contributes to productive scientific discussion and a positive effect on efficiency and dynamics of the citation of the article.
- The rights to the article are deemed transferred by the authors to the edition (the publisher) since the moment of the publication of the article in the printed or electronic version of journal.
Richards J., Weinman E.J. Uric acid and renal disease // J. Nephrol. — 1966. — 9. — 160-166.
Кинев К. Подагра. — М.: Медицина, 1980. — С. 128.
McAdams DeMarco M.A., Maynard J.W., Baer A.N., Gelber A.C., Young J.H., Alonso A. et al. Diuretic use, increased serum urate levels, and risk of incident gout in a population-based study of adults with hypertension: the Atherosclerosis Risk in Communities cohort study // Arthritis Rheum. — 2012. — 64. — 121-9.
Mateus M.P., Cruz C.M., Alves de Matos A.C. et al. Prevalence and characterization of uric gout disease in a rheumatology outpatient’s clinic // Ann. Rheum. Dis. — 2001. — Vol. 60 (Suppl. 1). — 328.
Коваленко В.М., Шуба Н.М., Корнацький В.М. Сучасний стан ревматологічної служби в Україні // Укр. ревматол. журн. — 2001. — Т. 5–6, № 3–4. — С. 3-7.
Krishnan E. Chronic kidney disease and risk of incident gout among middle-aged men: a seven-year prospective observational study // Arthritis Rheum. — 2013. — 65. — 3271-3278.
Juraschek S.P., Kovell L.C., Miller E.R. et al. Association of kidney disease with prevalent gout in the United States in 1988-1994 and 2007-2010 // Semin. Arthritis Rheum. — 2013. — 42. — 551-561.
Obermayr R.P., Temml C., Gutjahr G. et al. Elevated uric acid increases the risk for kidney disease // J. Am. Soc. Nephrol. — 2008. — 19. — 2407-2413.
Feig D.I. Uric acid: a novel mediator and marker of risk in chronic kidney disease? // Curr. Opin. Nephrol. Hypertens. — 2009 Nov. — 18(6). — 526-530.
Moriwaki Y. Effects on uric acid metabolism of the drugs except the antihyperuricemics // J. Bioequiv. Availab. — 2014. — 6 (1). — 10-17. doi: 10.4172 jbb.1000173
Kong L.D., Cai Y., Huang W.W. et al. Inhibition of xanthine oxidase by some chinese medicinal plants used to treat gout // J. Ethnopharmacol. — 2000. — 1–2. — 199-207.
Khanna D., Fitzgerald J.D., Khanna P.P. et al. American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia // Arthritis Care Res. — 2012. — 64. — 1431-4446.
Choi H.K. A prescription for lifestyle change in patients with hyperuricemia and gout // Curr. Opin. Rheum. — 2010. — 22. — 165-172.
Keitel R., Keitel W. Therapy of gout. Management of an acute attack — secondary prevention // MMW Fortschr. Med. — 2000. — 142 (12). — 48-50.
Dalbeth N., Wong S., Gamble G.D., Horne A., Mason B., Pool B., Fairbanks L., McQueen F.M., Cornish J., Reid I.R., Palmano K. Acute effect of milk on serum urate concentrations: a randomised controlled crossover trial // Annals of the rheumatic diseases. — 2010. — 69 (9). — 1677-82.
Rosenfeldt F.L. Metabolic supplementation with orotic acid and magnesium orotate // Cardiovasc. Drugs Ther. — 1998. — 12 Suppl. 2. — 147-52.
Gaĭsin I.R., Valeeva R.M., Maksimov N.I., Iskhakova A.S., Khodyrev L.A., Shilina L.V. Magnesium orotate in treatment of chronic hypertension in pregnant women // Kardiologiia. — 2013. — 53 (9). — 33-9.
Stepura O.B., Martynow A.I. Magnesium orotate in severe congestive heart failure (MACH) // International Journal of Cardiology. — 2009. — 134 (1). — 145-7.
Martynov A.I., Akatova E.V. Fifteen years experience of the use of magnesium preparations in patients with mitral valve prolapse // Kardiologiia. — 2011. — 51(6). — 60-5.
Jellinek H., Takаcs E. Morphological aspects of the effects of orotic acid and magnesium orotate on hypercholesterolaemia in rabbits // Arzneimittelforschung. — 1995. — 45(8). — 836-42.